Gusmão, R, Quintão, S, McDaid, D, Arensman, E, Van Audenhove, C, Coffey, C, et al. Antidepressant utilization and suicide in Europe: an ecological multi-national study. PLoS One
2013; 8: e66455.
OECD. Health at a Glance: Europe 2012. OECD Publishing, 2012.
McManus, S, Meltzer, H, Brugha, T, Bebbington, P, Jenkins, R (eds). Adult Psychiatric Morbidity in England, 2007: Results of a Household Survey. NHS Information Centre for Health and Social Care, 2009.
Wittchen, HU, Jacobi, F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol
2005; 15: 357–76.
Wittchen, HU, Jacobi, F, Rehm, J, Gustavsson, A, Svensson, M, Jönsson, B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol
2011; 21: 655–79.
Evans-Lacko, S, Brohan, E, Mojtabai, R, Thornicroft, G. Association between public views of mental illness and self-stigma among individuals with mental illness in 14 European countries. Psychol Med
2012; 42: 1741–52.
Mojtabai, R. Mental illness stigma and willingness to seek mental health care in the European Union. Soc Psychiatry Psychiatr Epidemiol
2010; 45: 705–12.
Anderson, IM, Ferrier, IN, Baldwin, RC, Cowen, PJ, Howard, L, Lewis, G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol (Oxf)
2008; 22: 343–96.
Lingam, R, Scott, J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand
2002; 105: 164–72.
European Commission. Mental Health. Part 1: Report (Special Eurobarometer 345/Wave 73.2).
European Commission, 2010.
European Commission. Mental Well-being
. European Commission, 2006.
McCabe, CJ, Thomas, KJ, Brazier, JE, Coleman, P. Measuring the mental health status of a population: a comparison of the GHQ-12 and the SF-36 (MHI-5). Br J Psychiatry
1996; 169: 516–21.
Ware, JE Jr, Gandek, B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol
1998; 51: 903–12.
Kelly, MJ, Dunstan, FD, Lloyd, K, Fone, DL. Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods. BMC Psychiatry
2008; 8: 10.
The World Bank. World Development Indicators 2012.
World Bank, 2012.
Alonso, J, Angermeyer, MC, Bernert, S, Bruffaerts, R, Brugha, TS, Bryson, H, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand
2004; 109 (suppl 420): 55–64.
Ohayon, MM, Lader, MH. The use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry
2002; 63: 817–25.
Mojtabai, R, Olfson, M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clinical Psychiatry
2014; 75: 169–77.
Pratt, LA, Brody, DJ, Gu, Q. Antidepressant Use in Persons Aged 12 and over: United States, 2005–2008
. U.S. Department of Health and Human Services, 2011.
Stagnitti, MN. Antidepressant Use in the U.S. Civilian Noninstitutionalized Population, 2002. Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality, 2005.
Dunn, RL, Donoghue, JM, Ozminkowski, RJ, Stephenson, D, Hylan, TR. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol (Oxf)
1999; 13: 136–43.
Pound, P, Britten, N, Morgan, M, Yardley, L, Pope, C, Daker-White, G, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med
2005; 61: 133–55.
Hynd, A, Roughead, EE, Preen, DB, Glover, J, Bulsara, M, Semmens, J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf
2008; 17: 1091–9.
Corrigan, P, Markowitz, FE, Watson, A, Rowan, D, Kubiak, MA. An attribution model of public discrimination towards persons with mental illness. J Health Soc Behav
2003; 44: 162–79.
Mossakowski, KN, Kaplan, LM, Hill, TD. Americans' attitudes toward mental illness and involuntary psychiatric medication. Soc Ment Health
2011; 1: 200–16.
Kvaale, EP, Gottdiener, WH, Haslam, N. Biogenetic explanations and stigma: a meta-analytic review of associations among laypeople. Soc Sci Med
2013; 96: 95–103.
Pescosolido, BA, Martin, JK, Long, JS, Medina, TR, Phelan, JC, Link, BG. “A disease like any other”? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am J Psychiatry
2010; 167: 1321–30.
Rüsch, N, Todd, AR, Bodenhausen, GV, Corrigan, PW. Biogenetic models of psychopathology, implicit guilt, and mental illness stigma. Psychiatry Res
2010; 179: 328–32.
Schomerus, G, Schwahn, C, Holzinger, A, Corrigan, PW, Grabe, HJ, Carta, MG, et al. Evolution of public attitudes about mental illness: a systematic review and meta-analysis. Acta Psychiatr Scand
2012; 125: 440–52.
Evans-Lacko, S, Knapp, M, McCrone, P, Thornicroft, G, Mojtabai, R. The mental health consequences of the recession: economic hardship and employment of people with mental health problems in 27 European countries. PLoS One
2013; 8: e69792.
Cotterchio, M, Kreiger, N, Darlington, G, Steingart, A. Comparison of self-reported and physician-reported antidepressant medication use. Ann Epidemiol
1999; 9: 283–9.
Kwon, A, Bungay, KM, Pei, Y, Rogers, WH, Wilson, IB, Zhou, Q, et al. Antidepressant use: concordance between self-report and claims records. Med Care
2003; 41: 368–74.